Mirum Pharmaceuticals, INC. (MIRM) — 10-Q Filings

All 10-Q filings from Mirum Pharmaceuticals, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Mirum Swings to Profit on Robust Q3 Product Sales Growth — Nov 4, 2025 Risk: medium
Mirum Pharmaceuticals, Inc. reported a significant increase in product sales, reaching $133.01 million for the three months ended September 30, 2025, up from $9
Mirum Pharma's Q2 Revenue Jumps 66% on Strong Product Sales — Aug 6, 2025 Risk: medium
Mirum Pharmaceuticals, Inc. reported product revenue of $50.0 million for the three months ended June 30, 2025, a significant increase from $30.0 million in the
Mirum Pharmaceuticals Files Q1 2025 10-Q — May 7, 2025 Risk: medium
Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
Mirum Pharma Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first
Mirum Pharmaceuticals Q2 2024 10-Q Filing — Aug 7, 2024 Risk: medium
Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from product sales and license and other revenue. K
Mirum Pharmaceuticals, Inc. Files 10-Q for Q1 2024 — May 8, 2024 Risk: low
Mirum Pharmaceuticals, Inc. (MIRM) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Mirum Pharmaceuticals, Inc. filed its 10-Q report for the period

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX